variability depends on liver function, on the intricate interactions between host-and tumor-related factors and on the possibility of undergoing beneficial treatments. Unfortunately, only few individuals with HCC are good candidates for potentially curative treatments, such as surgical resection and liver transplantation, since HCC is often diagnosed only at an advanced stage. Early HCC detection and clear-cut guidelines based on precise tumor classification are therefore crucial in order to choose the right treatment options and achieve better survival in HCC cases.
Despite considerable progress that has been made in understanding the molecular mechanisms of HCC, there is still a lack of complete understanding of the link between disease or infection and carcinogenesis ( fig. 1 ). Treatment options are limited when the HCC is not diagnosed in its early stage.
Currently, patient's prognosis and treatment can be determined using the Barcelona Classification [4] or alternatively, especially in eastern world, by the Tokyo [5] or the CUPI scores [6] . Patients within the same Barcelona Classification stage still have a variable course of their disease. Different attempts have been made to classify these tumors on a molecular basis in order to optimize prognosis and treatment. The development of the new 'omics' technologies, in particular microarray-based gene expression profiling provides a new insight into the molecular genetics of HCC and also contributes to its molecular classification.
Microarray Technology Application on HCC
Microarray technology has been widely applied to study the molecular and genomic mechanisms in liver carcinogenesis. Molecular profiling is a promising tool for HCC classification in order to optimize prognosis prediction and treatment for an individual patient. Microarray studies have allowed the identification of the molecular signature of HCC tumors that depict biological Sequential changes during HCC development. Normal liver that undergoes chronic hepatitis or cirrhosis progresses through hyperplastic and dysplastic stages. During these stages, cytogenetic alterations occur which led to evasion of apoptosis, to the promotion of tissue invasion and metastasis. aggressiveness yielded through deregulation of specific genes and molecular pathways, including the extracellular matrix, the cytoskeleton, oncogenes, tumor suppressor genes, immune response-related genes, apoptosis-related genes, signal transduction/translational regulatory genes ( WNT , TGFB , MAPK , EGFR , IGFR and MET/HGF ) and genes related to biotransformation/metabolism [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Gene signatures associated with tumor liver tissues allowed the prediction of early recurrence [9, 18] and patient survival [7] after surgery. Interestingly, some studies reported gene expression signatures associated with the non-tumor adjacent liver tissue that provide an additional value in prognosis prediction [19] [20] [21] [22] ( table 2 ) .
Gene Signature Associated with Prognosis
Microarray studies reported many gene signatures and showed their usefulness in the prediction of HCC prognosis and selection of therapeutic strategies. Prognostication is a vital component in clinical management of HCC patients and, in this context, gene expression profiling has allowed to stratify HCCs into several clinically relevant subgroups that were previously unrecognized by conventional methods [7, 8, 17, 23] .
The HCC subgroups displayed different cellular differentiation and biological behavior that correlate well with prognosis and may allow better patient stratification for treatment than the current clinical HCC staging systems. The study by Thorgeirsson and group [7] reported that human HCC can be subdivided into 2 subclasses that are associated with survival based on gene expression data. The poor survival group, Class A, showed a strong expression signature of cell proliferation, anti-apoptosis genes, as well as genes involving ubiquitination and histone modification, suggesting their involvement in the progression of HCC. On the contrary, Class B, a subclass characterized by high survival, had a completely different expression signature. It is possible that these 2 subclasses of HCC might represent different cellular origins, but it can be caused by considerable molecular heterogeneity within each HCC subclass.
Subsequently, the same group [8] analyzed the gene expression profiling of 139 HCC patients and identified 2 subtypes of HCC. One subtype exhibited the characteristics of hepatoblasts while the other of differentiated hepatocytes. Individuals with HCC who shared the gene expression pattern with fetal hepatoblasts had a poor prognosis. The gene expression pattern of this subtype of HCC included markers of hepatic oval cells, suggesting that it may arise from hepatic progenitor cells.
The existence of 2 broad categories of HCCs, one with and the other without a 'high-proliferation' gene expression signature, has been confirmed in multiple, independent studies [24] . Most have found that tumors of the high proliferation group are more aggressive and less histologically differentiated than the group without this expression signature.
Boyault et al. [17] refined this molecular classification system by identifying 6 groups of HCC (G1-G6) that were characterized by distinct clinical, genetic and molecular characteristics, including viral infection, activation of PI3K/AKT or WNT pathway and p53 mutations.
Tumors G1-G3 exhibited more chromosomal instability and had worser prognosis than G4-G6 HCCs and showed some similarities with the molecular classification by Lee et al. [7, 8] , like the overexpression of proliferation and DNA metabolism genes, poor survival and hepatoblast characteristics. This molecular classification not only provides prognostic information, but also facilitates the development of targeted therapies for HCC as the activation of specific pathway, particularly AKT and WNT pathways which are closely associated with subgroups G1-G2 and G5-G6, respectively. Furthermore, the authors identified and validated a robust 16-gene signature to classify HCC tumors into the 6-group transcriptomic classification. This signature might help in determining alterations of specific pathways and to predict putative response to targeted drugs [17] . Another study [23] classified HCCs in 4 groups based on epithelial cell adhesion molecule (EpCAM) expression and circulating levels of alpha-fetoprotein. EpCAM-positive cases had features of more aggressive HCC, with molecular characteristic of hepatic progenitor cells, while EpCAM-negative HCC displayed the molecular characteristics of mature hepatocytes. The inclusion of circulating alpha-fetoprotein levels in the classification allowed a sub-classification into 4 groups with different prognosis.
Gene Signature Associated with Etiology
The majority of HCC cases develop on underlying chronic liver diseases. As above, different risk factors are associated with HCC and in this contest, gene signatures associated with different etiologies have been reported [25] [26] [27] [28] [29] [30] . Microarray studies indicated that HBV and HCV infections lead to the development of liver cancer by different molecular mechanisms. Using the microarray technique, Honda et al. [25] reported differential gene expression profiles in HCCs from viral hepatitis B and C, suggesting that the molecular mechanisms responsible for the pathogenesis of HCC differ between HBV and HCV infections. The authors identified specific subsets of genes that are able to classify tissue according to HBV and HCV infection. Closer examination of these clustered genes suggested that genes for induction of apoptosis, those for cell cycle arrest and those for extracellular matrix degrading were upregulated in chronic hepatitis B, whereas genes with anti-apoptotic effects, those for cell cycle acceleration and those for extracellular matrix storage were upregulated in hepatitis C. Furthermore, in chronic hepatitis, expression of genes involved in the inflammation process was relatively predominant in HBVpositive HCCs while those linked with anti-inflammatory response genes were comparatively predominant in chronic hepatitis C. Okabe et al.
[26] identified a gene signature that is correlated with the infection status and type of hepatitis virus. They found that genes involved in drug metabolism and carcinogen detoxification were differentially regulated between HCV-positive and HBVpositive HCCs. Analysis of these profiles along with clinicopathological data also facilitated the identification of genes associated with tumor differentiation and vessel invasiveness. Similarly, Iizuka et al. [27] identified 83 genes that are differentially expressed between HCV-positive and HBV-positive HCCs. The HBV-related HCCs were characterized by a higher expression of imprinted genes (H19, IGF2) and genes related to signal transduction, transcription and metastasis, whereas HCV-related HCC displayed a higher expression of detoxification and immune response-related genes. Other studies showed that HBV and HCV infections may involve the alteration of different signaling pathways [31, 32] , thereby underlining the differential features of HCC progression. The identification of genes defining virus type-specific expression profiles may contribute to develop novel tools for the diagnosis and treatment of HBV-and HCV-associated HCCs.
Gene Signature Associated with Recurrence and Metastasis
Some microarray studies have identified signatures associated with prognosis, some with recurrence after treatment and some with the development of metastases. The poor outcome of HCC patients partly results from postsurgical recurrence of the primary tumor. Gene expression profiling has been therefore used in the attempt of better understanding of the molecular mechanisms involved in HCC recurrence and in identification of cancer patients with metastatic potential.
Ye et al. [18] described a gene signature that can classify metastatic HCC and identified genes relevant to metastasis and patient survival. Their findings supported the hypothesis that genes favoring metastatic progression are initiated in the primary tumors. Furthermore, they identified osteopontin as a lead gene in the signature that could act both as a diagnostic marker and a potential therapeutic target for metastatic HCC.
Several microarray studies identified gene signature associated with vascular invasion that is considered as a predictive factor for recurrence after surgical resection of the tumor. The study by Ho et al. [33] identified 14 genes correlated with vascular invasion, which can classify patients with high or low risk of occurrence of vascular invasion and recurrence after curative hepatectomy. This stratification of HCC patients could allow the identification of high risk patients in need of closer follow-up and, possibly, those who would benefit from adjuvant treatment.
Chen et al. [13] reported a proliferation gene signature that significantly correlated with the presence of vascular invasion. Most of the genes were associated with cell cycle progression. In another study, Budhu et al. [20] reported that livers from metastatic HCC patients had a different gene expression pattern compared with the livers from patients without metastatic HCC, and showed a 17-gene signature predictor of HCC venous metastasis. Their findings described that liver tissues from metastatic HCC patients showed a global decrease in the production of pro-inflammatory Th1-like cytokines and an increase in the production of anti-inflammatory Th2-like cytokines. It suggested that a unique immunological profile is activated to promote HCC metastases.
Similarly, Wang et al. [34] identified a 57-gene signature that stratified HCC patients with different risks of recurrence while Iizuka et al. [9] identified a 12-gene signature that could classify early-and late-stage HCCs. Since these genes are immune-related, it would be possible to hypothesize that signature-driven immunotherapy could be considered to reduce recurrence and invasion of HCC.
Gene Signatures Associated with the Non-Tumor Liver Tissue
Microarray technology has been also used to study gene expression to predict HCC outcome in non-tumor liver tissue, usually affected by chronic hepatitis or cirrhosis, [19] [20] [21] [22] . In 2008, Hoshida et al. [19] reported a 186-gene signature from liver tissue adjacent to the tumor that predicted survival after surgery for HCC and also predicted the outcome of liver cirrhosis.
Using the Gene Set Enrichment Analysis, the authors identified a gene signature that correlated with good prognosis containing genes associated with normal liver function, including hepatic lipase, plasma proteins, cytochromes and several drug-metabolizing enzymes, and a gene signature that correlated with poor prognosis containing genes associated with inflammation, including those related to interferon signaling, activation of nuclear factor-κB and signaling by tumor necrosis factor α.
These results highlight the potential role of non-tumor liver tissue in predicting the outcome in patients with early HCC. Most importantly, this signature could provide relevant information regarding the risk of neoplastic transformation of cirrhotic liver tissue [21] . These results suggest that this signature may represent not only a prognostic biomarker for the identification of cirrhotic patients at high risk of developing HCC, but it could have an important effect on approaches to tumor surveillance.
The adjacent non-tumor liver tissue also seems to be important for the development of intrahepatic metastases. This was described in the study by Budhu et al. [20] , in which a 17-gene signature was reported, including different interleukins and interferon-gamma genes, which could predict venous metastases.
These studies support the view that liver tissue surrounding the tumoral lesion is an extremely useful source of molecular information especially for the identification of subjects at high risk of developing HCC and possibly as a guide for chemoprevention.
Conclusion
HCC is a particularly complex disease, and the integration of all features of HCC including tumor stage, etiology, response to therapy, tumor recurrence and molecular characteristics are required to better understand its development and to plan an effective treatment. Gene expression profiling is certainly a powerful tool that can be extremely useful in the attempt of understanding HCC pathogenesis. During the past few years, there was a great progress in translational HCC research leading to a better understanding of the biological significance of molecular signatures in HCC. This will be crucial for better HCC management, especially in the era of personalized medicine approach in HCC treatment. This will permit a more comprehensive staging and assessment of tumor progression and, at the same time, evaluate whether a more personalized diagnosis will lead to improved outcome in HCC patients.
Summary
• HCC is the fifth most commonly occurring cancer and the third leading cause of cancer-related deaths every year worldwide. The etiology of HCC seems to be multifactorial, and several events seem to be necessary for malignant transformation to occur.
• Hepatocarcinogenesis is a complex multistep process involving a number of different genetic alterations mostly accompanied by chronic hepatitis and liver cirrhosis, which ultimately lead to malignant transformation of the hepatocyte. These molecular changes leading to a heterogeneous molecular profile.
• The major challenge is the identification of molecular biomarkers specific for HCC to facilitate early diagnosis, prognosis and treatment. The introduction of these molecular markers in clinical practice could guide treatment thus improving the outcome in HCC patients.
• Gene expression profiling using microarray technologies provides a powerful approach to understand the molecular mechanism of HCC development and to identify the molecular markers that could classify tumors and predict clinical outcomes such as survival, recurrence and metastasis.
• The integration of molecular and clinical data could allow the identification of new molecular targets and use these targets to develop new prevention, detection, diagnosis and treatment options for patients with HCC.
